Zhejiang Ausun Pharmaceutical Co., Ltd. (SHA:603229)
6.71
-0.02 (-0.30%)
Nov 17, 2026, 3:00 PM CST
SHA:603229 Revenue
Zhejiang Ausun Pharmaceutical had revenue of 142.64M CNY in the quarter ending September 30, 2026, a decrease of -13.07%. This brings the company's total for the last twelve months to 757.05M, up 0.79% year-over-year. In the year 2025, Zhejiang Ausun Pharmaceutical had annual revenue of 792.76M, down -0.32%. That makes Zhejiang Ausun Pharmaceutical the 21,754th largest company in the world by revenue and 3,984th in China.
Revenue (ttm)
757.05M
Revenue Growth
+0.79%
P/S Ratio
7.31
Revenue / Employee
570.07K
Employees
1,328
Market Cap
5.54B
Revenue by Segment
Fiscal year ended Dec 31, 2025 See the full SHA:603229 breakdown
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 792.76M | -2.53M | -0.32% |
| Dec 31, 2024 | 795.29M | -21.48M | -2.63% |
| Dec 31, 2023 | 816.77M | 52.22M | 6.83% |
| Dec 31, 2022 | 764.55M | 194.85M | 34.20% |
| Dec 31, 2021 | 569.70M | 160.45M | 39.21% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. It does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Youcare Pharmaceutical Group | 2.36B |
| Chengdu Kanghua Biological Products | 1.21B |
| R&G PharmaStudies | 957.42M |
| Wuhan Keqian Biology Co.,Ltd | 786.77M |
| PharmaResources (Shanghai) | 724.75M |
| Jiangsu Aidea Pharmaceutical Group | 716.78M |
| Beijing Hotgen Biotech | 470.60M |
| Hangzhou Biotest Biotech | 452.12M |